Prevail Therapeutics Inc. (NASDAQ:PRVL)’s share price was up 5.4% during trading on Tuesday . The company traded as high as $15.17 and last traded at $15.00, approximately 106,998 shares were traded during mid-day trading. An increase of 4% from the average daily volume of 102,969 shares. The stock had previously closed at $14.23.
A number of brokerages have weighed in on PRVL. Wedbush reissued a “buy” rating and set a $20.00 target price on shares of Prevail Therapeutics in a report on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Prevail Therapeutics in a research note on Tuesday, November 12th. Finally, Zacks Investment Research cut shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 29th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Prevail Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.50.
The company has a quick ratio of 17.05, a current ratio of 17.05 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $11.93.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC bought a new position in shares of Prevail Therapeutics during the third quarter worth about $47,000. Blackstone Group Inc acquired a new position in Prevail Therapeutics during the 2nd quarter valued at about $66,000. Point72 Hong Kong Ltd acquired a new position in Prevail Therapeutics during the 2nd quarter valued at about $106,000. California State Teachers Retirement System bought a new position in Prevail Therapeutics in the 3rd quarter worth about $142,000. Finally, Morgan Stanley bought a new position in Prevail Therapeutics in the 2nd quarter worth about $166,000. 78.00% of the stock is owned by institutional investors.
Prevail Therapeutics Company Profile (NASDAQ:PRVL)
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Featured Article: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.